U.S. regulators scrutinize peptide therapies more closely
U.S. health regulators are increasing oversight of therapeutic peptides, a class of drugs used in treatments for diabetes, obesity, and other conditions. The move comes as more peptide-based medicines enter clinical trials and the market, raising questions about safety, manufacturing standards, and labeling. This heightened scrutiny could shape the future of peptide drug approvals and patient access.